Clinical Trial Update: Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study [Phase 3]

View source ↗

Summary

A Phase 3 randomized, placebo-controlled trial evaluated ferric carboxymaltose (FCM) for treating heart failure with iron deficiency; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Iron Deficiency

Drugs mentioned

• Ferric carboxymaltose (Injectafer) (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Heart Failure, Iron-deficiency | Phase 3 | Status: COMPLETED | Results posted: 2024-07-03